Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Global home evaluations' attendance
研究概览
简要总结
The low prevalence of rare diseases hinders the design of clinical studies with sufficient statistical power to demonstrate the efficacy of new drugs. This can only be achieved by setting up international multicentre studies, which is challenging due to a lack of objective, universal outcome measures that generate high-quality, reproducible data. One of the hurdles in attaining universal outcome measures for clinical trials is the difficulty to capture and distinguish ambulatory from non-ambulatory, autonomous and assistive or involuntary movements. This makes a trial assessing the ambulatory phase very challenging at this moment. Excluding many participants from trials and many patients from access to medication.
Integration and validation of the technology in trials, research and patients' lives is essential in overcoming this hurdle. For example, in dystrophinopathies separate outcome measures exist for ambulant and non-ambulant participants, but the relation between these outcome measures or a transitional outcome measure/end point is largely missing.
Following an exhaustive literature review, several tools have been selected to remotely follow various symptoms of neuromuscular patients including weakness, pain, fatigue, cognitive defects, motor impairments (including loss of dexterity, ataxia...), metabolic, respiratory and cardiac troubles, contractures, tremor, falls, hypo or hypersomnia... The toolbox includes common measures for all patients but may include additional measures specific to the patient's symptoms (hence in turn to the patients' disease).
The measurements are designed to not be invasive, intrusive or burdensome for the patient.
DT4RD is going to leverage state-of-the art technology, clinical rating scales and psychometric/data analysis to deliver fit for purpose remote clinical assessments of mobility to ensure maximum patient benefit, specifically:
- Compare face to face clinical data collected in hospital with Patient Generated Data recorded remotely
- Examine how sensors can enhance measurement potentially at home and during clinical visits
- Promote a clear focus on user centered design and the integration of technology
- Use reliability and validity analyses to equate any common measures (those with the same or a similar construct)
- Demonstrate a proof-of-concept model into which different measures can be interchangeable
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 60 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged between 12 and 60 years
- •Patients with a genetically confirmed/molecular-proven neuromuscular or neurometabolic disease*
- •Patients experiencing walking difficulties in the home and at high risk of limiting participation and walking outside of the home.
- •Written informed consent
- •Able to comply with all protocol requirements, including video recording
- •Affiliated to or beneficiary of a social security scheme (for France)
排除标准
- •Patients with undefined diagnosis or any diagnosis other than neuromuscular or neurometabolic disease
- •Patient walking 10m in less than 10s
- •Guardianship/trusteeship
- •Pregnant or nursing women
- •Patients having relevant concomitant pathologies that, in the appreciation of the investigator could interfere with protocol compliance
- •Patients not being affiliated with local social security (for France)
研究组 & 干预措施
Principal
干预措施: 2MWT (Other)
Principal
干预措施: ACTIVLIM (Other)
Principal
干预措施: PREM (Other)
Principal
干预措施: MFM32 (Other)
Principal
干预措施: MyoGrip (Other)
Principal
干预措施: QOL-gNMD (Other)
Principal
干预措施: Spirometry (Diagnostic Test)
Principal
干预措施: Acceleromerty (Device)
Principal
干预措施: 10mWT (Other)
Principal
干预措施: PUL (Other)
Principal
干预措施: NSAA (Other)
Principal
干预措施: NSAD (Other)
Principal
干预措施: TANS (Other)
Principal
干预措施: MyoPinch (Other)
Principal
干预措施: MyoQuad (Other)
Principal
干预措施: SF-MPQ (Other)
Principal
干预措施: FSS (Other)
Principal
干预措施: IPAQ (Other)
Principal
干预措施: Rang of motion (Other)
Principal
干预措施: Goniometry (Device)
Principal
干预措施: Video captured monitoring (Other)
Principal
干预措施: Activity monitoring (Device)
结局指标
主要结局
Global home evaluations' attendance
时间窗: Through study completion, an average of 1 year
Proportion of home assessments carried out compared to the number of home assessments planned
次要结局
- Compliance regarding using of the spirometer at home(Through study completion, an average of 1 year)
- Correlation of home and hospital spirometer Forced vital capacity measurements(Through study completion, an average of 1 year)
- Compliance regarding using of the LINKS sensors device at home(Through study completion, an average of 1 year)
- Compliance regarding using of the activity sensor at home(Through study completion, an average of 1 year)
- Correlation of home and hospital spirometer peak expiratory flow measurements(Through study completion, an average of 1 year)
- Compliance with filling out questionnaires at home(Through study completion, an average of 1 year)
- Correlation of home and hospital spirometer forced expiratory volume in 1 second measurements(Through study completion, an average of 1 year)
- Compliance regarding achievement of video tasks at home(Through study completion, an average of 1 year)
